Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating disease through the inhibition of the complement system, which is a component of the immune system, at the level of C3, the central protein in the complement cascade. The company's clinical program targets C3 with Phase 3 clinical trials of its main product candidate, APL-2, in multiple indications. APL-2 has the potential to be a treatment that address the limitations of existing treatment options or provide a treatment option. The company is also conducting a Phase 2 trial of APL-2 in glomerular diseases, including C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy and lupus nephritis.

Bed, Bath & Beyond is an omnichannel retailer providing products, services and solutions for the home and life events. The company operates an ecommerce platform consisting of various websites and applications, including bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, and facevalues.com. The company sells an assortment of domestics merchandise and home furnishings. Domestics merchandise includes categories such as bed linens and related items, bath items and kitchen textiles. Home furnishings include categories such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings (including furniture and wall decor), consumables and certain juvenile products.

Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.

Landec designs, develops, manufactures and sells health and wellness products for food and biomaterials markets. The company operates its business in two reportable business segments: Curation Foods, and Lifecore. The Curation Foods business is comprised of Curation Foods' packaged vegetables business sold primarily under the Eat Smart? brand, O Olive Oil & Vinegar? olive oils and wine vinegars, and Yucatan? and Cabo Fresh? guacamole and avocado food products. Lifecore is involved in the manufactures of pharmaceutical-grade sodium hyaluronate in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

Mack-Cali Realty is a real estate investment trust. The company owns and operates a real estate portfolio comprised of Class A office and office/flex properties located primarily in the Northeast. The company performs various real estate leasing, management, acquisition and development on an in-house basis. The company's industry segments are: commercial and other real estate and multi-family real estate and services. The company provides leasing, property management, acquisition, development, construction and tenant-related services for its commercial and other real estate and multi-family real estate portfolio. The company's multi-family services business also provides similar services for third parties.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

New Residential Investment is a holding company. Through its subsidiaries, the company is a real estate investment trust mainly focused on investing in, and managing investments related to residential real estate. The company is externally managed and advised by an affiliate of Fortress Investment Group LLC. The company's portfolio is composed of mortgage servicing and origination related assets, residential securities (and associated call rights) and loans and other investments. A mortgage servicing right provides a mortgage servicer with the right to service a pool of residential mortgage loans in exchange for a portion of the interest payments made on the underlying residential mortgage loans.

PGT Innovations is a holding company. Through its subsidiaries, the company is a manufacturer and supplier of residential impact-resistant windows and doors. The company manufactures lines of mass-custom aluminum and vinyl windows and doors and porch enclosure products targeting both the residential repair and remodeling and new construction end markets. The company's brands include: PGT? Custom Windows & Doors, CGI? Windows and Doors and WinDoor?. The geographic regions in which the company conducts business include the Southeastern U.S., Western U.S., Gulf Coast, Coastal mid-Atlantic, the Caribbean, Central America, and Canada. The company operates as one segment, the manufacture and sale of windows and doors.

Savara is an orphan lung disease company. The company's drug development pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor in development for pulmonary alveolar proteinosis and in development for nontuberculous mycobacterial lung infection; and AeroVanc, an inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.